Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes

Rita Cortesi; Laura Ravani; Francesca Rinaldi; Peggy Marconi; Markus Drechsler; Marco Manservigi; Rafaela Argnani; Enea Menegatti; Elisabetta Esposito; Roberto Manservigi

doi:10.1016/j.ijpharm.2012.06.042

Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: a preliminary study as possible vaccine against genital herpes

Int J Pharm. 2013 Jan 20;440(2):229-37. doi: 10.1016/j.ijpharm.2012.06.042. Epub 2012 Jun 26.

Authors

Rita Cortesi¹, Laura Ravani, Francesca Rinaldi, Peggy Marconi, Markus Drechsler, Marco Manservigi, Rafaela Argnani, Enea Menegatti, Elisabetta Esposito, Roberto Manservigi

Affiliation

¹ Department of Pharmaceutical Sciences, University of Ferrara, Ferrara, Italy. [email protected]

PMID: 22743007
DOI: 10.1016/j.ijpharm.2012.06.042

Abstract

The purpose of this study was to investigate the potential of intranasal immunization with non-ionic surfactant vesicles (NISV) containing either the secretory recombinant form of glycoprotein B (gBs) of herpes simplex virus type 1 or a related polylysine reach peptides (DTK) for induction of protective immunity against genital herpes infection in mice. NISV were prepared by lipid film hydration method. The mean diameter of vesicles was around 390 nm for DTK-containing NISV (DTK-NISV) and 320 nm for gB1s-containing NISV (gB1s-NISV). The encapsulation efficiency of the molecules was comprised between 57% and 70%. After 7-14 day NISV maintained stable dimensions and a drug encapsulation higher than 48%. We showed that intranasal immunization with gB1s-NISV induces gB-specific IgG antibody and lymphoproliferative responses, whereas vaccination with DTK-NISV was not able to generate a gB-specific immune response. Our results indicate that vaccination of BALB/c mice with gB1s-NISV induced Th1 responses, as characterized by increased titre of IG2a in plasma and IFN-production in CD4+ splenic cells. Intranasal immunization with gB1s-NISV could elicit 90% (almost complete) protection against a heterologous lethal vaginal challenge with herpes simplex virus type 2. These data may have implications for the development of a mucosal vaccine against genital herpes.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Administration, Intranasal
Animals
Antibodies, Viral / blood
Chlorocebus aethiops
Cytokines / metabolism
Drosophila Proteins / administration & dosage
Drosophila Proteins / immunology
Herpes Genitalis / blood
Herpes Genitalis / immunology
Herpes Genitalis / prevention & control*
Herpes Simplex Virus Vaccines / administration & dosage
Herpes Simplex Virus Vaccines / immunology
Herpes Simplex Virus Vaccines / therapeutic use*
Herpesvirus 2, Human / immunology
Humans
Immunization / methods*
Immunoglobulin G / immunology
Immunoglobulin G / metabolism
Liposomes / administration & dosage
Liposomes / chemical synthesis
Liposomes / therapeutic use*
Lymphocyte Activation / immunology
Mice
Mice, Inbred BALB C
Particle Size
Protein Precursors / administration & dosage
Protein Precursors / immunology
Spleen / immunology
Spleen / metabolism
Surface-Active Agents / administration & dosage
Surface-Active Agents / chemistry
Surface-Active Agents / therapeutic use*
Tachykinins / administration & dosage
Tachykinins / immunology
Vero Cells
Viral Envelope Proteins / administration & dosage
Viral Envelope Proteins / immunology
Viral Envelope Proteins / therapeutic use

Substances

Antibodies, Viral
Cytokines
Drosophila Proteins
Herpes Simplex Virus Vaccines
Immunoglobulin G
Liposomes
Protein Precursors
Surface-Active Agents
Tachykinins
Tk protein, Drosophila
Viral Envelope Proteins
glycoprotein B, human herpesvirus 1